Canterbury Vets Ltd
Canterbury Vets is a locally owned and operated practice, providing large and companion animal veterinary services and products since 1993. Our clinic is located at 363 West Street, Ashburton
BRAVECTO® CHEW is available as a chewable oral flea and tick treatment for dogs – providing 3 months protection.
Why choose Bravecto chew for your dog:
Active Ingredients
Bravecto contains fluralaner.
Dosage
For oral use only.
Bravecto chewable tablets should be administered in accordance with the following (corresponding to a dose of 25-56 mg fluralaner/kg body weight within one weight band):
Bodyweight (kg) of dog
Very Small (2* – 4.5kgs) Bravecto 112.5 mg
Small (> 4.5 – 10kgs) Bravecto 250 mg
Medium (> 10 – 20kgs) Bravecto 500 mg
Large (> 20 – 40kgs) Bravecto 1000 mg
Very Large (> 40 – 56kgs) Bravecto 1400 mg
*For use in dogs from 8 weeks of age and over 2kg.
For optimal control of tick and flea infestation, the Bravecto chewable tablet should be administered at 3 monthly intervals. Bravecto chewable tablet can be administered all year round.
Additional Information
Pack Sizes:
1 x single dose packs
Safety/Warnings
Mild and transient gastrointestinal symptoms such as diarrhoea/ vomiting/ inappetence/ drooling related to the route of administration of the product may be observed.
Fluralaner is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence, itching and very rarely neurological signs including tremors, ataxia and seizures. Most adverse reactions are self-limiting and of short duration. If you have any concerns, please speak to your veterinarian.
If hypersensitivity to the active substance or to any of the excipients is known or suspected, do not use this product. Use with caution in dogs with pre-existing epilepsy.
The safety has not been established in puppies less than 8 weeks old and/or dogs weighing less than 2 kg. The safety has not been established for treatment with this product when administered at intervals shorter than 8 weeks.